ImmunoMet Therapeutics is a clinical-stage biotechnology company developing metabolism-targeted anti-fibrotic and anti-cancer therapies, with lead candidate IM156, a protein complex 1 (PC1) inhibitor. IM156 targets the OXPHOS pathway to decrease the supply of energy and anabolic precursors required to drive fibrotic disease and tumor growth, and is solely owned by the company. The U.S. FDA has cleared an IND for IM156 in idiopathic pulmonary fibrosis (IPF) and granted it Orphan Drug Designation. ImmunoMet plans to initiate a single-site U.S. Phase 1 study in 32 healthy volunteers in Q1 2021 to characterize safety, tolerability, pharmacokinetics, and effects, with data intended to inform a Phase 2 trial in IPF. The company recently completed a Korean Phase 1 trial of IM156 in oncology patients and reported good tolerability at doses previously tested in humans. Financially, ImmunoMet has raised $31M to date and has closed $7.0M in new financing to help fund the Phase 1 program. ImmunoMet Therapeutics focuses on targeting cellular metabolism to develop novel anti-cancer and anti-fibrotic therapies. Its lead candidate, IM156, is a potent Protein Complex 1 (PC1) inhibitor that targets the oxidative phosphorylation (OXPHOS) pathway and is solely owned by the company. IM156 completed a Phase 1 study in healthy volunteers with good tolerability and the company has established target engagement. ImmunoMet also owns a large library of biguanides that it may develop internally or with partners for multiple indications. The company plans a food effect study in Q1 2022 to optimize IM156 dosing and is preparing for Phase 2 oncology trials, aiming to be in the clinic in multiple oncology indications by Q4 2022. Founded in 2015 and headquartered in JLABS @ TMC in Houston, ImmunoMet is advancing clinical and development activities supported by recent financing. ImmunoMet Therapeutics is a development-stage biotechnology company focused on utilizing cellular metabolism to develop novel anti-tumor and immuno-oncology therapies. Its lead program, IM156, is an OXPHOS inhibitor expected to enter a Phase 1 clinical trial in the second quarter of 2017. The company is also developing an immuno-oncology program, IM188, in combination with immunotherapies including an anti-PD1; IM188 is in late-stage lead optimization and has demonstrated tumor regression in a renal cancer model. ImmunoMet intends to use the new funding to advance the Phase 1 study for IM156 and the preclinical studies of its immuno-oncology program focused on inhibiting immune suppressor cells. The company is a spinoff of HanAll and is headquartered at JLABS in Houston. Leadership includes founder, Chairman and CEO Dr. Sung-wuk Kim and COO Benjamin R. Cowen. ImmunoMet Therapeutics is a development-stage biotechnology spinoff of HanAll Biopharma led by CEO Sung-wuk Kim. The company has developed novel technology intended to disrupt cancer cell growth and enhance anti-cancer immunity, with potential application across a broad range of difficult-to-treat cancers. Its lead compound, IM156, for the treatment of glioblastoma was expected to enter Phase 1 clinical development in the second half of 2016. The company raised $5.2M in a Series A funding round and intends to use the proceeds to advance research and clinical development programs. ImmunoMet also plans to establish its worldwide headquarters in Houston, TX and to fund general corporate purposes. The company is focused on moving its lead program into clinical testing and supporting broader R&D efforts.

Total raised

$27M

Funding rounds

4

Latest round

Equity

Latest activity

Feb 2021